Hypothermia for Refractory Status Epilepticus. Corry JJ, Dhar R, Murphy T, Diringer MN. Neurocrit Care 2008;9(2): [189][190][191][192][193][194][195][196][197]. INTRODUCTION: Status epilepticus (SE) can be refractory to conventional anticonvulsants, requiring anesthetic doses of medications to suppress seizures. This approach carries significant morbidity, is associated with a high fatality rate, and may not always control SE. Hypothermia has been shown to suppress epileptiform activity experimentally, but has not previously been used as a primary modality to control SE in humans. METHODS: Four patients with SE refractory to benzodiazepine and/or barbiturate infusions were treated with hypothermia (target temperature: 31-35 • C) using an endovascular cooling system. All received continuous EEG monitoring, three were on midazolam infusions and one had recurrent seizures on weaning from pentobarbital. RESULTS: Therapeutic hypothermia was successful in aborting seizure activity in all four patients, allowing midazolam infusions to be discontinued; three achieved a burstsuppression pattern on EEG. After controlled rewarming, two patients remained seizure-free, and all four demonstrated a marked reduction in seizure frequency. Adverse events included shivering, coagulopathy without bleeding, and venous thromboembolism.
W hen status epilepticus (SE) is refractory to conventional antiepileptic medications, it is typically treated with anesthetic doses of barbiturates, benzodiazepines, or propofol. Even if these treatments end the SE, there is, nonetheless, significant associated morbidity and mortality. Better treatments, with fewer adverse effects, are needed to stop the seizures and reduce the risk of long-term neurological consequences from this condition.
In recent years, induced reduction of body temperature in the intensive care unit has become a common therapy for coma associated with cerebral injury. Mild (32-34 • C) systemic hypothermia has been shown in randomized clinical trials to improve neurological outcome after cardiac arrest (1, 2) . It has become a recommended treatment for out-of-hospital cardiac arrest after ventricular fibrillation, and there also is evidence of its possible value following cardiac arrest that is associated with other abnormal heart rhythms or that occurs in the hospital (3) . In addition, mild hypothermia has been applied to the treatment of patients with traumatic brain injury and increased intracranial pressure, with benefit in some circumstances (4) . There is extensive evidence that cooling reduces synaptic transmission in the brain, and recent work suggests that a key mechanism for this change may be the reduction of transmitter release from presynaptic vesicles (5) . All of these results raise the question of whether hypothermia also might be an effective intervention for refractory SE.
This question has been addressed in a variety of experimental seizures. A body temperature of 28 • C in rats reduces ictal discharges and prevents hippocampal neuronal loss from kainate-induced SE (6) , and a temperature of 32.5 • C decreases the widespread neuronal loss seen in SE induced by inhaled flurothyl (7) . Focal cooling of the hippocampus to 23 to 26 • C decreases seizure severity and afterdischarge duration during hippocampal kindling in the rat (8) . These studies provide strong evidence for antiepileptic and neuroprotective effects in animals.
In humans, hypothermia has been long known to suppress epileptiform discharges (9) , and moderate (30-31 • C) body temperature reduction previously has been used in combination with thiopental coma to control refractory SE (10) . However, the current study by Corry and coworkers is the first to use hypothermia as a therapy for refractory SE in humans without simultaneous barbiturate infusion. The four patients in this study did not have preexisting epilepsy, but presented with severe generalized SE that was refractory to several conventional antiepileptic medications and infusions of pentobarbital, phenobarbital, or midazolam. Each patient's temperature was reduced to a range of 31 to 35 • C by circulating cooled saline through balloons on the surface of an inferior vena cava catheter introduced through the femoral vein. The temperature was lowered until the seizures stopped on EEG monitoring; then, midazolam and vasopressor infusions were reduced or weaned entirely. Typically, the cooling period lasted 24 hours, and the infrequent seizures that occurred after warming did not require repeat cooling. A significant adverse effect was deep vein thrombophlebitis in three of the patients. The two surviving patients are seizure-free, and one is described as having no observable neurological deficits.
This study suggests that mild systemic hypothermia is a practical and effective method to treat refractory SE. Does this mean that this method is ready to be widely introduced into clinical practice? Not yet! Several key questions remain to be answered:
• What is the optimal cooling technique? Would an external cooling blanket be an effective alternative to the endovascular approach and have a lower risk of thrombophlebitis? In treating SE, speed is essential. Would an initial intravenous infusion of iced saline achieve more rapid cooling and improve efficacy? The current study appears to show that mild cooling is usually sufficient for seizure control; however, this finding needs to be verified in a larger series.
• Does systemic hypothermia result in improved outcomes relative to other treatment options? The four patients in the current study had prolonged pharmacoresistant SE and, therefore, a rather unfavorable neurological prognosis. While it is noteworthy that cooling stopped seizures in all these patients, the overall outcomes for the group were not impressive. A better assessment of the neurological benefits of cooling could be made using hypothermia earlier in the SE treatment protocol, at the point when it has been demonstrated that the SE is refractory to bolus doses of conventional antiepileptic medications (e.g., lorazepam, phenytoin, phenobarbital, or levetiracetam) but before starting continuous intravenous infusions of benzodiazepines, barbiturates, or propofol. A subject group defined by these criteria would have a better overall prognosis than the patient cohort in the current study of Corry and coworkers, and modest improvements in outcomes might be easier to demonstrate.
• Would systemic hypothermia be better tolerated and safer than the alternate pharmacological treatments? In addition to thromboembolism, adverse effects of concern with hypothermia include shivering, coagulopathy, pH changes, electrolyte disturbances, and immunosup-pression. An advantage of hypothermia appears to be a low risk of hypotension as compared with barbiturate infusion. The cooling method, body temperature, the duration of hypothermia, and comorbid conditions would be important factors influencing the occurrence of adverse effects.
• If cooling therapy ultimately were shown to reduce the neurological sequelae of SE, could it also reduce the risk of subsequent epilepsy? It is not uncommon for severe SE to result in chronic recurrent seizures in survivors. Prevention of neuronal loss may or may not result in an antiepileptogenic effect.
Only a randomized, controlled clinical trial could definitively determine whether systemic hypothermia has superior safety and outcomes relative to pharmacological treatment for SE that is not controlled with conventional antiepileptic medications. The work of Curry and coworkers demonstrates that such a trial is justified and would meet the condition of equipoise. 
COMMENTARY
M en who have epilepsy, particularly those with focal epilepsy, are far less likely to ever father a pregnancy than unaffected males (1). Sexual dysfunction, as manifested by decreased libido, erectile dysfunction, and anorgasmia, occurs in 20 to 50% of men with epilepsy (1, 2) . A loss of pubic hair, gynecomastia, and testicular atrophy are among the possible physical signs. In some patients, sexual dysfunction may relate to hypogonadism, that is, lower biologically available testosterone (BAT), and abnormal or decreased sperm production. Testosterone exists in three principal forms: 1) tightly bound to sex hormone-binding globulin (SHBG; 45-50%), 2) loosely bound to albumin (50-55%), and 3) unbound to albumin (1-2%) (1). Albumin-bound and unbound testosterone comprise the clinically important BAT, whereas testosterone bound to SHBG is not biologically available (1) . Some studies, including the current one by Talbot and colleagues, have found decreased BAT and increased SHBG associated with enzyme-inducing antiepileptic drugs (AED), such as carbamazepine and pheny-toin, but no alteration of these testosterone components with nonenzyme-inducing AEDs, such as lamotrigine (3, 4) . Among men with focal epilepsy, BAT levels are normal in 89% of men who are 20 to 30 years of age and in 73% of men between 30 and 40 years of age; thus, the percentage within normal levels is much higher than what would be expected, given the previously mentioned relative infertility incidence (1) .
This discrepancy and the results of the Talbot et al. study indicate that other elements must be interposed in any link between epilepsy and males with infertility. The Talbot et al. study offered one example: "a significant correlation . . . between sexual function and indices of anxiety and depression." Stress, depression, and stigma-induced social isolation impair the ability to attract partners and marry (2, 5) . Psychosocial stress also may influence the development of hypogonadism, as stress may activate the hypothalamo-pituitary axis, increasing the formation of adrenocorticotropic hormone (ACTH) and endorphin; both of these hormones inhibit gonadotrophin secretion and reproductive function (1, 6) .
The effect of epileptic discharges on fertility (particularly when abundant) merits consideration. Patients with focal epilepsy are more disadvantaged reproductively than those with primary generalized seizures (7, 8) . Temporal lobe epileptic discharge likely disrupts hypothalamic functions associated with reproduction, but direct proof of any contribution to male hypogonadism and, therefore, to the loss of male fertility, is lacking. Afferents from the medial amygdaloid nucleus and the amygdaloid-hippocampal area project directly into the medial preoptic area of the hypothalamus-an area principally involved in reproductive functions (9) . Electrical kindling of the rat amygdala increased serum testosterone in one study (10) . However, the fact that kindled male rats have far fewer seizures than do patients with temporal lobe epilepsy diminishes the value of the kindling model for human male reproductive assessment (11) . Of interest, the medial preoptic area also is involved in motivational aspects of male copulatory behavior; thus, lesions of this area may diminish interest and sexual arousal (9) .
Enzyme-inducing AEDs (e.g., carbamazepine and phenytoin) decrease BAT in two ways: 1) by suppressing gonadal testosterone synthesis, and 2) by increasing hepatic production of SHBG (1). While the Talbot et al. study confirmed these effects, their finding that BAT levels exceeded the "androgen threshold" for normal sexual function in both patients and controls suggests that, as with most side effects, AED dose exerts a significant influence. Some types of epilepsy and patients with refractory epilepsy require substantially higher AED dosing than others. For example, the percentage of patients who fall into various epilepsy syndromes or subtypes and who have been seizure-free for more than 1 year ranges from over 80% (e.g., idiopathic generalized epilepsy) to between 24 and 54% (e.g., other focal epilepsies) to 3% (e.g., temporal lobe epilepsy, with dual pathology) (12, 13) . Moreover, enzymeinducing AEDs generally are preferred by prescribing physicians for focal epilepsies, whereas nonenzyme-inducing AEDs are selected for generalized epilepsies (14) (15) (16) . When combining data on seizure severity and AED preferences, it appears that enzyme-inducing AEDs used at higher doses may underlie the higher incidence of infertility in males with focal seizure disorders (7) .
The following provides several epilepsy management implications for male patients with epilepsy:
• Establishing whether the seizure disorder is focal or primary generalized, using ictal semiology and one or more EEGs, is important.
• Depression is often hidden by men with epilepsy. Judicious enquiry of the patient and those living with him may be required to ascertain a diagnosis.
• Probing for the presence of sexual dysfunction through history and physical examination can be helpful.
• Reproductive endocrine levels can be measured by determination of the bioactive portions of total BAT and SHBG.
• Patients with seizures that originate focally and are intractable can be considered for resective surgery.
• If economic, employment, and driving factors permit, an attempt can be made to replace the patient's enzymeinducing AEDs with nonenzyme-inducing ones. (9):665-669. BACKGROUND: Antiepileptic drugs are routinely given after craniotomy.
Though phenytoin (PHT) is still the most commonly used agent, levetiracetam (LEV) is increasingly administered for this purpose. This retrospective study compared the use of LEV and PHT as monotherapy prophylaxis following supratentorial neurosurgery. METHODS:
Patients receiving LEV monotherapy after supratentorial craniotomy were reviewed and compared to a control group of patients receiving PHT monotherapy. RESULTS: One of 105 patients taking LEV and 9/210 patients taking PHT had seizures within 7 days of surgery (p = 0.17). Adverse drug reactions requiring change in therapy during hospitalization occurred in 1/105 patients taking LEV and 38/210 patients taking PHT (p < 0.001). Among patients followed for at least 12 months, 11/42 (26%) treated with LEV vs 42/117 (36%) treated with PHT developed epilepsy (p = 0.34); 64% remained on LEV, while 26% remained on PHT (p = 0.03). CONCLUSIONS: Both levetiracetam (LEV) and phenytoin (PHT) were associated with a low risk of early postoperative seizures and a moderate risk of later epilepsy. LEV was associated with significantly fewer early adverse reactions than PHT and with a higher retention rate in patients who were followed for at least 1 year and developed epilepsy.
A ntiepileptic drug (AED) prophylaxis to prevent seizures in a patient who has not yet had seizures but is at risk, seems like a reasonable approach; however, it is more complicated than it appears. While seizure prevention in at-risk patients seems logical at face value, this reasoning presupposes that the possibility of an adverse drug reaction from the AED is lower than the probability of harm from a seizure. Thus, in order for the approach to be valid, the population under study must: 1) be at significant risk for seizures, 2) have some expectation that the seizures might cause harm, and 3) be at low risk of an adverse drug reaction from the AED.
Neurosurgeons have considered patients to be at significant risk for seizures after supratentorial surgery (especially, following surgeries for brain tumors and traumatic brain injury), although the actual risk is highly variable and only in the range of about 3%. Additionally, even a single convulsion immediately after neurosurgery may cause harm because of the increased intracranial pressure created by strong muscular contractions. Therefore, it has been a common practice to provide phenytoin as seizure prophylaxis after neurosurgery. The main problem with this approach is that phenytoin commonly causes side effects that are annoying and, less commonly but more importantly, can cause serious reactions, including anticonvulsant hypersensitivity syndrome, serious rash, purple glove syndrome, and necrosis when extravasated. Consequently, a tug of war has persisted between proponents and adversaries of AED prophylaxis following surgery. An American Academy of Neurology practice parameter clearly suggests that AED prophylaxis is use-ful for severe traumatic brain injury but does not recommend it for newly diagnosed brain tumors (1, 2) . A separate metaanalysis of the more generic case of supratentorial neurosurgery did not find AED prophylaxis to be beneficial (3) . Thus, there is a need for studies that can determine the efficacy of AED prophylaxis for a variety of situations.
If an AED is to be administered, which one is the most efficacious following supratentorial neurosurgery? Increasingly, levetiracetam is replacing phenytoin for prophylaxis after neurosurgery. Levetiracetam has straightforward pharmacokinetics and few drug interactions or common side effects; it is simple to use, usually well tolerated, and available in an intravenous formulation. These properties make it well suited for use in acutely ill patients, such as in patients after craniotomy. Behavioral side effects, such as irritability, can occur but are unlikely to be manifest or an issue in acutely ill patients. The favorable characteristics of levetiracetam have led many neurosurgeons to alter their traditional practice of providing phenytoin for prophylaxis after supratentorial neurosurgery and to use levetiracetam instead. However, there is little data to support the use of levetiracetam in this manner.
In the article by Milligan et al., the investigators retrospectively reviewed their experience with 105 patients who took levetiracetam and compared it with 210 patients who used phenytoin as AED prophylaxis for seizures after supratentorial craniotomy. Not surprisingly, they found levetiracetam was better tolerated than phenytoin and seemingly equally efficacious; thus, their finding is evidence that levetiracetam may be preferable to phenytoin. However, the study suffers from the limitations of a retrospective design: the phenytoin group had higher median age, fewer primary brain tumors, and a smaller proportion with preoperative seizures, which could have skewed the results. These issues might have been addressed by a case-control design that matched levetiracetam and phenytoin patients. It is generally believed that levetiracetam is considerably better tolerated than phenytoin in routine clinical practice, so even the small number of patients in this study allowed them to find statistical superiority of tolerability in favor of levetiracetam quiet easily. However, even if one treatment were more efficacious, it probably would be superior by only a small amount. Thus, the limited number of patients in this study makes it difficult to find any expected degree of difference in efficacy between the drugs.
Despite some limitations, the study by Milligan and colleagues does report outcomes that are clinically useful and extends the general clinical observations that levetiracetam is better tolerated than phenytoin in the specific setting of AED prophylaxis after supratentorial craniotomy. A randomized, controlled trial with a placebo arm that compares phenytoin with levetiracetam would be very informative. The placebo arm would be an important aspect of the study design, since, as discussed, controversy still exists regarding across-the-board use of AED prophylaxis following supratentorial craniotomy. Such a study could allow close monitoring and adjustment of phenytoin to address its fickle nature, which might yield a smaller difference in tolerability. However, the fact that phenytoin use requires so much care and attention is the exact reason that it is likely to lose its preeminent role in seizure prophylaxis after neurosurgery. Until a definitive study is performed, it may be reasonable to use levetiracetam instead of phenytoin for seizure prophylaxis after supratentorial craniotomy-if the practitioner chooses to use AED prophylaxis at all in this setting.
by Nathan B. Fountain, MD a triad of multiple seizure types (atonic, tonic, atypical absence, myoclonic, and generalized tonic-clonic), cognitive dysfunction, and slow spike-and-wave activity (slower than 2.5 Hz) on EEG.
LGS can be symptomatic secondary to a brain insult, such as perinatal anoxia or cerebral dysgenesis, or cryptogenic in a previously normal child.
LGS accounts for 1 to 4 percent of childhood epilepsy but constitutes a larger proportion (10%) of all refractory epilepsy, as most patients never achieve seizure freedom (1).
Glauser et al. report a randomized, controlled trial of rufinamide for refractory LGS in subjects aged 4 to 37 years. Rufinamide is a structurally novel triazole-derivative antiepileptic drug (AED). The proposed mechanism of action is the limitation of sodium-dependent action potential firing (2) . Rufinamide has a broad efficacy spectrum in animal models of epilepsy. Two large double-blind, placebo-controlled trials demonstrated rufinamide to be efficacious and well tolerated as adjunctive therapy for partial seizures in adults, although it is not yet FDA-approved for this indication (2) . In 647 subjects with refractory partial seizures, rufinamide add-on therapy was superior to placebo at 400-, 800-, and 1,600-mg doses (treatment difference vs placebo were 11%, 16%, and 17%, respectively) (2) . In a second trial of 313 patients with refractory partial epilepsy, the mean seizure frequency in the rufinamide group (target dose 3,200 mg) showed a 20.4% decrease in the median seizure frequency compared with a 1.6% median increase in the placebo group. The ≥50% responder rate was 28.2% for rufinamide versus 18.6% for placebo (2) .
Glauser and colleagues report that rufinamide was significantly superior to placebo for both primary study endpoints: percent change in seizure frequency and parent/guardian ratings of seizure severity. Tonic-atonic seizures, which often are disabling because of associated falls and injuries, were significantly reduced. Similarly, absence and atypical absence seizures were decreased, although the frequency of these often subtle but innumerable daily seizures may be underestimated without video-EEG monitoring. Adverse effects included sedation (24%) and vomiting (21%); six patients (8%) in the rufinamide group discontinued because of adverse effects. Cognitive or psychiatric adverse events were less common in the rufinamide group (17.6%) than in the placebo group (23.4%). Based on these results, rufinamide is efficacious and well tolerated for all seizures, including tonic-atonic seizures, for LGS.
Integrating the results of this study into clinical practice will be less straightforward. There are no class I or II studies for the treatment of early LGS. Broad-spectrum AEDs are preferred, as they may have activity against multiple seizures types and are less likely to exacerbate generalized seizures. Valproate is usually the treatment of choice for initial therapy of LGS, despite the absence of controlled trials assessing efficacy (3, 4) . Several newer AEDs have demonstrated efficacy for refractory LGS in class I studies. A Cochane review (5) and the American Academy of Neurology/American Epilepsy Society guidelines (6) support the efficacy of felbamate, lamotrigine, and topiramate as adjunctive therapy for LGS (predominantly for atonic or astatic seizures) in adults and children. Felbamate use is constrained by potential hepatotoxicity and aplastic anemia. Clobazam (not approved for use in the United States) and other benzodiazepines are commonly used when initial valproate therapy fails (3, 4) . Narrow-spectrum AEDs, such as carbamazepine and tiagabine, may exacerbate certain seizure types (e.g., atypical absence and myoclonic) or even precipitate nonconvulsive status epilepticus (SE). Anecdotal reports and uncontrolled studies provide preliminary support for efficacy of other broad-spectrum AEDs, such as levetiracetam and zonisamide (1) . When AEDs fail, vagus nerve stimulation and corpus callosotomy improve seizure control, particularly for atonic seizures (1) .
What is rufinamide's place among these various treatment options? There are no head-to-head comparative trials of commonly used AEDs for LGS. Although the magnitude of seizure reduction in this rufinamide trial by Glauser et al. is similar to or better than that reported in trials of felbamate, topiramate, and lamotrigine, no direct comparisons can be made because of differences in methodology, baseline seizure frequency, concomitant AEDs, titration schedules, and outcome measures. This cohort may have been more refractory than other randomized LGS trials, with very high baseline monthly seizure counts. Forty percent of rufinamide patients were taking lamotrigine and 27% were taking topiramate-AEDs that were not available at the time of prior LGS randomized trials.
Likewise, adverse effect rates cannot be directly compared. Rufinamide was initiated at 10 mg/kg/day, divided twice daily, and increased by 10 mg/kg/day every 2 days to a maximal dose of 45 mg/kg/day (or 3,200 mg/day for adults >70 kg), divided twice daily. The rate of dose escalation was rapid; most patients reached the target dose by 7 days and nearly 90% by 14 days. A slower dose escalation may be better tolerated, particularly for patients already taking multiple AEDs. This report does not give details of adverse effect rates stratified by the number or type of baseline concomitant AEDs. This information will be essential to optimize clinical use. Similarly, the relationship between adverse effects and rufinamide serum levels was not reported; in the future, serum levels may help to individualize dosing regimens.
The main advantages of rufinamide are a good cognitive and psychiatric adverse effect profile, few drug interactions (although valproate may increase rufinamide levels), and the ability to rapidly escalate dosing in as few as 7 days. Because AED polytherapy is typical in LGS, avoidance of drug interactions and AED adverse effects are the paramount concerns. Patients with LGS often have seizure clusters and exacerbations of seizure frequency; thus, the ability to rapidly achieve improvements in seizure frequency with rufinamide also is a major advantage.
Safety concerns and clinical experience govern how quickly a new AED is adopted into common practice. Other newer AEDs, such as topiramate and lamotrigine, were FDA-approved for treatment of partial seizures in adults and children as well as for LGS, and there was extensive familiarity with their clinical use, safety, and tolerability before they were widely used for LGS. In contrast, fewer than 2,000 patients with epilepsy have been treated with rufinamide in double-blind or extension phases of clinical trials, with time periods ranging from less than 1 month to more than 4 years (2). This exposure is far too low to detect rare side effects, such as hypersensitivity reactions, hematologic adverse effects, and hepatotoxicity. Because of the limited FDA indication for rufinamide, it may take a significant amount of time to reach a safety comfort level-approximately 100,000 patient exposures are necessary for the detection of rare idiosyncratic adverse events.
SE is common in LGS and was seen in 4% (3/74) of patients in the rufinamide group versus 0% in the placebo group. The type of SE (convulsive or nonconvulsive) was not reported. Other sodium channel blockers, such as carbamazepine, may increase the frequency of some seizure types and even precipitate SE. Overall, SE occurred in 0.9% of patients in rufinamide clinical trials run to date. Whether the higher SE rate in this trial is a rufinamide effect or merely due to chance will become clear with wider use.
High seizure severity and overall poor prognosis justify rapid adoption of rufinamide for refractory LGS. Rufinamide use is most appropriate when LGS patients have failed valproate, topiramate, and lamotrigine and probably before felbamate, other newer AEDs, vagus nerve stimulation, or corpus callosotomy is considered. Whether rufinamide should be used earlier in LGS will depend on clinical experience and future comparative clinical trials-is it more efficacious or better tolerated than available drugs, and is safety acceptable? For now, rufinamide is a welcome addition to the treatment armamentarium for this devastating epilepsy syndrome.
by Susan T. Herman, MD
